10.22.17 to 10.23.17
Dubai, United Arab Emirates

In South Asia, where the burden of enteric fever is thought to be highest, most typhoid studies have focused on urban areas. As a result, researchers have been unsure how well available data could be extrapolated to predominantly rural areas.

Families across the United States are sending their young children back to school. School preparations are not limited to buying school supplies. Parents should make sure their children are up-to-date with vaccinations.

This is Gul Rahim’s story of typhoid, as told to Attaullah Baig of Aga Khan University Hospital on January 7, 2017, and translated into English. The interview was conducted in Urdu and has been edited for clarity and length.

More than 300 researchers from 45 countries gathered in Kampala, Uganda in early April for the 10th International Conference on Typhoid and Other Invasive Salmonelloses.

When the 70th World Health Assembly (WHA) begins today in Geneva, Switzerland, it will be one of historic measure. Not only because the WHA be electing a new Director-General of the World Health Organization (WHO), but also because of its sheer scope.

For years, little was known of the typhoid burden in Africa, even though outbreaks of multi-drug resistant typhoid is becoming increasingly common. This lack of information spurred the Bill and Melinda Gates Foundation to fund the Typhoid Fever Surveillance in Africa Program (TSAP) through the International Vaccine Institute, a first-of-its-kind study established to shed light on true extent of the typhoid burden and multi-drug resistance distribution on the continent. The results from the TSAP, recently published in the Lancet Global Health, represent the most comprehensive and rigorous analysis of typhoid in Africa and could change our understanding of the disease burden across the continent.

Vaccines are healthcare’s first line of defense. From polio to pertussis, rubella to rotavirus, vaccination has saved more lives than any other medical advance in recent history.

Dr. Jan Holmgren Receives 2017 Albert B. Sabin Gold Medal Award

WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.

Pages